ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins50% CONFIDENCEOverall confidence: 50%How well the pin's source and references back up its dates.Weighted average of how firmly 1 reference, the source included, supports the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidence
ClinicalTrials.gov[1] lists 2027-05-17 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Regeneron Pharmaceuticals's phase 3 trial of REGN7508 in symptomatic venous thromboembolism reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery compared to acetylsalicylic acid. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
1.00